Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT05113745 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT05113745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05113745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Long-term Efficacy and Safety of AXS-12 in the Treatment of Cataplexy and Excessive Daytime Sleepiness in Subjects With Narcolepsy
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 20, 2021
Completion date
November 15, 2024
Enrollment
68 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cataplexy, excessive daytime sleepiness, narcolepsy